Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease
Colchicine was first used in Behcet's Disease (BD), in 1977. There are controversial reports of the efficacy of Colchicine in BD. For some experts the unresponsiveness of some patients could be explained by genetic difference between the Silk Road BD and sporadic BD from other parts of the world.
To test this hypothesis (the inefficacy of colchicine in the Silk Road BD), we designed a randomized double-blind controlled crossover study in Iran, which is in the middle of the Silk Road, and has the second highest prevalence of BD in the world.
|Study Design:||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||A Double Blind Cross Over Clinical Trial to Determine Colchicine Efficacy in Behcet`s Disease|
- Iranian Behcet's Disease Dynamic Activity Measurement (IBDDAM) [ Time Frame: 8 months ]
- Oral Aphthosis [ Time Frame: 8 months ]
- Genital Aphthosis [ Time Frame: 8 months ]
- Psuedofolliculitis [ Time Frame: 8 months ]
- Erythem Nodusom [ Time Frame: 8 months ]
- Joint Manifestations [ Time Frame: 8 months ]
|Study Start Date:||August 2002|
|Study Completion Date:||May 2006|
|Primary Completion Date:||October 2005 (Final data collection date for primary outcome measure)|
Active Comparator: Colchicine
Patients who received Colchicine and went on placebo after 4 months
100 mg Colchicine per day for 4 months
Other Name: Modacine
Placebo Comparator: Placebo
Patients who received placebo and went on Colchicine after 4 months
One tablet placebo per day for 4 months
Patients: They were selected as consecutive patients.
The entry criteria was: age between 14 and 60 years, confirmed diagnosis of Behcet's Disease, absence of major organ involvement (eye, brain, lung, and cardio-vascular involvement), having at least one active symptom, and no treatment for at least one month. Patients were explained the study design and they gave a signed written consent. During the two phases of study, if a major organ involvement appeared, the patient was moved out of the study. All patients fulfilled the new International Criteria for Behcet's Disease.
Method: patients were randomized at the study entry to take either colchicine or placebo. At 4 months, they were crossed over. Those who were taking colchicine went on placebo and those on placebo went on colchicine. Each patient tried therefore, both colchicine and placebo. The primary outcome was the effect of colchicine on the disease activity index, the IBDDAM (16-17). To calculate the overall IBDDAM of the baseline, the IBDDAM of the last 12 months (prior to the study) of each manifestation was calculated and added together. The overall disease activity index was then divided to the number of months (12 months) to have the mean activity index per month. IBDDAM was then measured every 2 months (in the middle and at the end, in each arm of the study). The total IBBDAM of the 4 months was then divided by 4 to have the mean activity index per month. The secondary outcome was to see how the individual symptoms responded to colchicine (IBDDAM of each manifestation).
Statistical analysis: The analysis was done by the intention to treat method. As the difference between IBDDAM before and after treatment had normal distribution Student T test for paired samples were used to evaluate the outcome in the colchicine and the placebo group. As the Levene's test showed the homogeneity of variance, ANOVA (one way) was used to test the effect of treatment (colchicine and placebo) and gender on patients' outcome. The dependent variable was the difference between IBDDAM (before and after the treatment). The independent variables were the treatment, and the gender. SPSS 15 was used for all statistical calculations.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00700297
|Iran, Islamic Republic of|
|Rheumatology research Center, Tehran UMS|
|Tehran, Iran, Islamic Republic of, 14114|
|Study Chair:||Fereydoun Davatchi, Professor||Rheumatology Research Center, Tehran University for Medical Sciences|
|Principal Investigator:||Bahar Sadeghi, MD||Rheumatology research Center, Tehran University for Medical Sciences|
|Principal Investigator:||Arash Tehrani Banihashemi, MD, MPH||Rheumatology Research Center, Tehran University for Mrdical Sciences|
|Principal Investigator:||Farhad Shahram, Professor||Rheumatology Research Center, Tehran University for Medical Sciences|